ArticleFrontiers in oncology2025
Global, regional, and national burden of ovarian cancer attributable to high body mass index, 1990-2021: insights from the global burden of disease study 2021.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Burden, Regional Trends and Risk Factors of Breast, Cervical, Uterine, and Ovarian Cancers in Sub-Saharan Africa, 1990-2023: The Global Burden of Disease 2023.International journal of environmental research and public health · 2026Article
- Artificial Intelligence in Lung Cancer: A Narrative Review of Recent Advances in Diagnosis, Biomarker Discovery, and Drug Development.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Building on established evidence linking excess body fatness to increased risk of ovarian cancer, this research aims to assess the global and regional disease burden of ovarian cancer attributable to high body mass index (BMI) from 1990 to 2021 using data from the Global Burden of Disease (GBD) study. Here, we specifically focus on quantifying trends in age-standardized mortality rates (ASMR) and age-standardized disability-adjusted life year rates (ASDR) to elucidate evolving epidemiological patterns and regional disparities. Methods: Comprehensive data were extracted from the GBD 2021 database to analyze trends in ASMR, ASDR, absolute deaths, and disability-adjusted life years (DALYs) attributable to high BMI-related ovarian cancer from 1990 to 2021, stratified by global, regional, and socio-demographic index (SDI) quintiles. The key methodological approaches included Joinpoint regression analysis to identify significant temporal changes in ASMR and ASDR trends and correlation analysis to determine associations between disease burden (ASMR/ASDR) and SDI. Additionally, future projections for ASMR and ASDR burdens from 2022 to 2050 were generated using a Bayesian Age-Period-Cohort (BAPC) framework, accounting for demographic shifts and inherent uncertainties. Results: Between 1990 and 2021, global ASMR and ASDR for ovarian cancer attributable to high BMI remained relatively stable. However, the absolute number of deaths and DALYs increased substantially over this period. ASMR and ASDR exhibited a strong positive correlation with SDI, with the highest burden observed in regions with SDI values between 0.7 and 0.8. While high-SDI regions experienced the greatest burden in both 1990 and 2021, an overall declining trend was observed. Conversely, regions across other SDI quintiles exhibited an increasing burden. BAPC projections suggest a continued global increase in the ovarian cancer burden attributable to high BMI, with global ASMR projected to reach 1.64 (95% uncertainty level (UI): 1.35-1.93) and ASDR to reach 54.63 (95% UI: 45.41-63.84) by 2050. Conclusion: This study highlights persistent and significant regional disparities in the ovarian cancer burden attributable to high BMI, strongly associated with SDI, and projects a concerning increase in the future global burden. Our collective findings underscore the urgent need for targeted and proactive interventions to mitigate the impact of high BMI on ovarian cancer outcomes worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.